| [1] |
Tilly H, Vitolo U, Walewski J, et al.
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann OncolAnn Oncol, 2012, 23(S7): vii78-vii82.
doi: 10.1093/annonc/mds273 |
| [2] |
Martelli M, Ferreri AJM, Agostinelli C, et al.
Diffuse large B-cell lymphoma[J]. Crit Rev Oncol HematolCrit Rev Oncol Hematol, 2013, 87(2): 146-171.
doi: 10.1016/j.critrevonc.2012.12.009 |
| [3] |
Mylam KJ, El-Galaly TC, Hutchings M, et al.
Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma[J]. Leuk LymphomaLeuk Lymphoma, 2014, 55(7): 1563-1569.
doi: 10.3109/10428194.2013.850165 |
| [4] |
Cheson BD, Fisher RI, Barrington SF, et al.
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin OncolJ Clin Oncol, 2014, 32(27): 3059-3067.
doi: 10.1200/JCO.2013.54.8800 |
| [5] |
Adams HJA, Nievelstein RAJ, Kwee TC.
Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis[J]. Br J HaematolBr J Haematol, 2015, 170(2): 185-191.
doi: 10.1111/bjh.13420 |
| [6] |
Meignan M, Gallamini A, Meignan M, et al.
Report on the first international workshop on interim-PET scan in lymphoma[J]. Leuk LymphomaLeuk Lymphoma, 2009, 50(8): 1257-1260.
doi: 10.1080/10428190903040048 |
| [7] |
应志涛, 王雪鹃, 宋玉琴, 等.
弥漫大B细胞淋巴瘤患者规范治疗后行18F-FDG PET/CT检查的预后意义[J]. 中华血液学杂志中华血液学杂志, 2012, 33(10): 810-813.
doi: 10.3760/cma.j.issn.0253-2727.2012.10.005 Ying ZT, Wang XJ, Song YQ, et al. Prognostic value of 18F-FDG PET/CT after first-line treatment in patients with diffuse large B cell lymphoma[J]. Chin J HematolChin J Hematol, 2012, 33(10): 810-813. doi: 10.3760/cma.j.issn.0253-2727.2012.10.005 |
| [8] |
丁重阳, 李天女, 孙晋, 等.
化疗中期及终末期18F-FDG PET/CT显像对弥漫性大B细胞淋巴瘤患者预后评估价值[J]. 中华核医学与分子影像杂志中华核医学与分子影像杂志, 2014, 34(6): 461-465.
doi: 10.3760/cma.j.issn.2095-2848.2014.06.010 Ding CY, Li TN, Sun J, et al. Prognostic value of interim and post-therapy 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2014, 34(6): 461-465. doi: 10.3760/cma.j.issn.2095-2848.2014.06.010 |
| [9] |
Pregno P, Chiappella A, Bellò M, et al.
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP[J]. BloodBlood, 2012, 119(9): 2066-2073.
doi: 10.1182/blood-2011-06-359943 |
| [10] |
The International Non-Hodgkin's Lymphoma Prognostic Factors Project.
A predictive model for aggressive non-Hodgkin's lymphoma[J]. N Engl J MedN Engl J Med, 1993, 329(14): 987-994.
doi: 10.1056/NEJM199309303291402 |
| [11] |
Sehn LH, Berry B, Chhanabhai M, et al.
The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP[J]. BloodBlood, 2007, 109(5): 1857-1861.
doi: 10.1182/blood-2006-08-038257 |
| [12] |
Zhou Z, Sehn LH, Rademaker AW, et al.
An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era[J]. BloodBlood, 2014, 123(6): 837-842.
doi: 10.1182/blood-2013-09-524108 |
| [13] |
宋腾, 王华庆, 张会来, 等.
改良国际预后指数(NCCN-IPI)对R-CHOP方案治疗弥漫大B细胞淋巴瘤的预后评估(附168例临床分析)[J]. 中国肿瘤临床中国肿瘤临床, 2015, 42(21): 1050-1055.
doi: 10.3969/j.issn.1000-8179.2015.21.977 Song T, Wang HQ, Zhang HL, et al. Prognostic significance of an enhanced international prognostic index(NCCN-IPI)for patients with diffuse large B-cell lymphoma treated with R-CHOP: a case report of 168 patients[J]. Chin J Clin OncolChin J Clin Oncol, 2015, 42(21): 1050-1055. doi: 10.3969/j.issn.1000-8179.2015.21.977 |
| [14] |
Bishton MJ, Hughes S, Richardson F, et al.
Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis[J]. Br J HaematolBr J Haematol, 2016, 172(2): 246-254.
doi: 10.1111/bjh.13831 |
| [15] |
Kanemasa Y, Shimoyama T, Sasaki Y, et al.
Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients[J]. Med OncolMed Oncol, 2017, 34(2): 29-.
doi: 10.1007/s12032-017-0885-6 |
| [16] |
Adams HJA, de Klerk JMH, Fijnheer R, et al.
Residual anatomical disease in diffuse large B-cell lymphoma patients with FDG-PET-based complete response after first-line R-CHOP therapy: does it have any prognostic value?[J]. J Comput Assist TomogrJ Comput Assist Tomogr, 2015, 39(5): 810-815.
doi: 10.1097/RCT.0000000000000270 |